MedTrace Logo

The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients

NCT04909164 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-05-16

No results posted yet for this study

Summary

The pragmatic clinical trial to elucidate optimal target population of immunotherapy from real-world lung cancer patients

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Immunnotherapy group

Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.

Sponsors & Collaborators

  • National Evidence-Based Healthcare Collaborating Agency

    collaborator OTHER_GOV

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Myung-Ju Ahn, M.D, Ph.D. · Samsung Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2025-07-30
Completion
2025-12-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04909164 on ClinicalTrials.gov